Epigallocatechin-3-gallate inhibits estrogen-induced activation of endometrial cells in vitro and causes regression of endometriotic lesions in vivo

Matthias W. Laschke, Christine Schwender, Schwender C, Scheuer C, Claudia Scheuer, Cláudia Scheuer, Brigitte Vollmar, Vollmar B, Menger MD, Michael D. Menger
Human Reproduction · 2008 · vol. 23(10) , pp. 2308–2318 · doi:10.1093/humrep/den245 · PMID:18603648 · W2144420473
Lab / animal OA: bronze CC0 ⤵ 50 in-corpus citations
📄 Open PDF View on OpenAlex View on PubMed View at publisher
⚙ AI-generated summary by gemini-2.5-flash-lite, 2026-06-06 ⓘ

Epigallocatechin-3-gallate inhibits estrogen-induced activation, proliferation, and VEGF expression of endometrial cells in vitro and causes regression of endometriotic lesions in vivo by reducing angiogenesis and blood perfusion.

One-sentence paraphrase of the abstract; not a substitute for reading it. No clinical advice. How this works

Abstract

BACKGROUND: Epigallocatechin-3-gallate (EGCG), the major component of green tea, is a pleiotropic substance, which may inhibit tumor growth via multiple intracellular signaling pathways. Herein, we studied whether EGCG may also be effective in the treatment of endometriosis. METHODS: We investigated the effect of EGCG on activation by estradiol (E(2)), proliferation and vascular endothelial growth factor (VEGF) expression of isolated hamster endometrial stromal cells and glandular cells in vitro using the water-soluble tetrazolium (WST)-1 colorimetric assay and western blot analysis. In the dorsal skinfold chamber model of Syrian golden hamsters, which were treated for 14 days with EGCG or vehicle, we further analyzed angiogenesis, blood perfusion and tissue integrity of both endometriotic lesions and ovarian follicles by intravital fluorescence microscopy and histology. RESULTS: We found that EGCG suppresses E(2)-stimulated activation, proliferation and VEGF expression of endometrial cells in vitro (all P < 0.05). Furthermore, EGCG selectively inhibited angiogenesis and blood perfusion (P < 0.05) of endometriotic lesions in vivo without affecting blood vessel development in ovarian follicles. Histology confirmed that EGCG-treatment induces regression of the endometriotic lesions. CONCLUSIONS: Our data indicate that EGCG might be a promising therapeutic agent in the treatment of endometriosis, preventing the establishment of new endometriotic lesions.

My notes (saved in your browser only)

Condition tags

endometriosis

MeSH descriptors

Angiogenesis Inhibitors Catechin Endometriosis Angiogenesis Inhibitors Angiogenesis Inhibitors Angiogenesis Inhibitors Animals Animals Catechin Catechin Catechin Catechin Cell Line Cell Line Cell Proliferation Cell Proliferation Cell Proliferation Cricetinae Cricetinae Endometriosis

Citation neighborhood (2-hop)

Papers in the corpus that this work cites (lower rings, blue) and that cite this one (upper rings, green). Dot size scales with the paper's in-corpus citation count — bigger dot = more influential within the endo/adeno field. Click a dot to open that paper. Outer rings show 2-hop neighbours — papers reached through the immediate citers/citees. [ collapse to 1-hop ]

References (57)

Cited by (50)

Source provenance

europepmc
last seen: 2026-10-16T06:09:50.462052+00:00
openalex
last seen: 2026-06-10T17:14:06.276822+00:00
pubmed
last seen: 2026-10-08T21:05:36.063128+00:00
License: CC0 · commercial use OK